Zacks Investment ResearchT3·1mo ago
ABVX Abivax SA American Depositary Shares
XNAS
86.50
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ABVX
$86.50
—
Key stats
$86.50
- 52-Week Range
- $69.81 – $148.83
- YTD
- -35.34%
- IV Rank (30D)
- 6.91
- Straddle Price
- $13.10
- P/C Vol Ratio
- 0.47
- Market Cap
- $7.7B
- Open
- $88.01
- Day Range
- $86.25 – $88.46
- Volume
- 423,693
- Prev Close
- $88.01
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.90 |
| Cost of Equity (CAPM) | 15.42% (VRP-adj) |
| WACC | 5.23% |
| Volatility Risk Premium | +15.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $102.65 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $90.48 |
| Bollinger Width / SMA20 | 18.3% (drives anchor stability) |
| Net Debt | $-0.6B |
Peers used for multiples: GILD, GSK, LLY, NTRA, NVS, RVMD, RYTM, TEVA
60-Day Conviction
95%
20-Day Fair Value
≈ by Nov 25, 2026
$87.40
α +1.0%
rank 60%
conviction
60%
40-Day Fair Value
≈ by Dec 24, 2026
$89.52
α +3.5%
rank 67%
conviction
92%
60-Day Fair Value
≈ by Jan 22, 2027
$91.02
α +5.2%
rank 66%
conviction
95%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 42.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 25.9× · 4 peers |
| Peer P/B | n/a | 0% | median 16.4× · 7 peers |
| Peer P/S | n/a | 0% | median 10.3× · 6 peers |
| Market Anchor (SMA50) | $102.65 | 60% | stability 76% (BB-width) |
| Options Expected (B-L 30d) | $86.11 | 40% | 40 strikes · skew +0.15 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $7.7B
- Employees
- 69
- List Date
- 2023-10-20
- CIK
- 0001956827
- Homepage
- https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a si…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 22.04% | -18.11% | -16.91% | -4.33% |
| Feb | -- | 3.26% | 29.29% | 8.81% | 13.79% |
| Mar | -- | 2.58% | -14.73% | -1.56% | -4.57% |
| Apr | -- | 7.37% | 20.88% | 2.10% | 10.12% |
| May | -- | -6.91% | -12.88% | 12.77% | -2.34% |
| Jun | -- | -1.93% | 20.47% | 2.75% | 7.10% |
| Jul | -- | -12.91% | 836.95% | -6.57% | 272.49% |
| Aug | -- | 8.08% | 12.63% | -10.46% | 3.42% |
| Sep | -- | -7.17% | 3.55% | -12.89% | -5.50% |
| Oct | 10.84% | -5.93% | 24.30% | -9.04%* | 5.04% |
| Nov | 4.00% | -16.94% | 26.28% | -- | 4.45% |
| Dec | 6.26% | -13.68% | 12.45% | -- | 1.68% |
| Total | 22.49% | -25.32% | 2109.17% | -30.21% | 519.03% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $90.48
SMA 50: $102.65
SMA 200: $114.73
Current: $86.50
EMA 12: $89.78
EMA 26: $93.64
MACD: -3.8670 | Signal: 0.7839
BEARISH
ADX (14): 32.92
TREND
+DI: 19.88
−DI: 32.15
Momentum Oscillators
RSI (14): 38.36
NEUTRAL
Stoch %K: 33.69
Stoch %D: 50.05
Williams %R: -80.54
Volume & Volatility
BB Upper: $97.98
BB Lower: $82.98
NEUTRAL
OBV: 36,014,305
Vol SMA 20: 1,162,298
Vol ROC: -35.70%
ATR: $4.22
True Range: $2.21
HV 20: 44.9%
HV 30: 52.5%
HV 60: 43.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
This report provides an in-depth analysis of ABVX, a biotech stock with recent news headlines and market metrics. Our overall assessment is BEARISH with a confidence level of 7 out of 10.
Key drivers for the bearish sentiment include:
- Technical indicators suggesting a weak trend and downward momentum.
- Recent news headlines focusing on potential takeover targets, which may not directly impact ABVX's fundamentals.
- High risk profile due to high volatility and beta relative to the market (1.00).
Primary risks to consider are:
- Volatility, with a stock volatility of 0.86, indicating above-average price movements.
- Potential earnings miss or guidance revision, which could lead to further declines.
Investment thesis: ABVX's recent performance may be driven by market sentiment and investor enthusiasm for biotech stocks. However, the company's fundamentals remain uncertain, and the options market is pricing in a higher level of volatility than historical averages.
Recent news sentiment impact: The positive sentiment from recent news headlines (Zacks Investment Research, GlobeNewswire Inc., etc.) has contributed to the stock's short-term gains but may not have a lasting impact on the company's underlying performance.
Technical Analysis
Trend Direction: Short-term: BEARISH (downward momentum), Medium-term: NEUTRAL (weak trend), Long-term: BEARISH (potential downtrend)
Support/Resistance Levels: Key price levels include:
- Lower Bollinger Band ($103.98)
- SMA 20 ($113.30)
- EMA 12 ($110.86)
Momentum Signals:
- RSI interpretation: Neutral (37.49) - no strong buying or selling signals.
- MACD signal: Bearish (crossover below signal line) - indicating downward momentum.
- Bollinger Bands position: Squeeze (price near the middle band) - potential for further price movement.
Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): 45168754.23 - no strong buying or selling signals.
- Volume Rate of Change: -21.26% - indicating decreased volume.
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles are positive, focusing on potential takeover targets and biotech industry trends.
Sentiment Assessment: Aggregate news sentiment is POSITIVE (60% positive, 30% neutral, 10% negative).
Catalyst Identification: No specific catalysts or earnings dates available.
Market Narrative: The market narrative suggests that ABVX's recent performance may be driven by market sentiment and investor enthusiasm for biotech stocks. However, the company's fundamentals remain uncertain.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta = 1.00).
Volatility Regime: Above-average volatility - stock moves with market amplification.
Options Market Signals:
- IV Rank: Medium (29.8%) - shows if volatility is historically high/low.
- Current IV: 97.0% - indicating above-average volatility.
- Expected Move: $18.30 (28 DTE) - medium-term move expected.
Market Context & Positioning
Sector Performance: Biotech sector performance has been strong, which may be contributing to ABVX's recent gains.
Institutional Activity: No strong institutional interest signals detected.
Correlation Analysis: High correlation with the market (R-squared = 0.85) - indicating amplification of market movements.
Relative Valuation: Position within trading range.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor include:
- Lower Bollinger Band ($103.98)
- SMA 20 ($113.30)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves are:
- Upper Bollinger Band ($122.62)
- EMA 26 ($114.60)
Time-Sensitive Catalysts: No specific earnings dates or product launches available.
Risk Management: Stop-loss levels and position sizing considerations:
- Use stop-loss orders to limit potential losses.
- Consider reducing position size due to high volatility and risk profile.
Please note that this analysis is based on the provided data, and actual performance may vary.
Generated
News
All ABVX news →
GlobeNewswire Inc.T3·1mo ago
The Motley FoolT3·3mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·3mo ago
BenzingaT3·4mo ago
The Motley FoolT3·4mo ago
The Motley FoolT3·5mo ago
GlobeNewswire Inc.T3·6mo ago
Showing 1–10 of 36
Page 1 of 4
ABVX Options Activity & IV Rank
ABVX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 64.4%
7-DTE IV: 68.5%
Expected Move: $13.10
7-DTE Move: $5.12
Days to Exp: 32 (2026-11-27)
Options Flow
Call Volume: 228
Put Volume: 108
P/C Volume: 0.474
BULLISH
Call OI: 756
Put OI: 391
P/C OI: 0.517
Total OI: 1,147
ATM Options Pricing
ATM Call: $7.10
ATM Put: $6.00
Call %: 8.2%
Put %: 6.9%
Chain Summary
Chain Volume: 13,221
Chain OI: 201,375
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 25th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
25%
vs own history
GEX tilt
-0.01
OI-weighted, today
Vanna tilt
+0.29
δ-sensitivity to IV
Charm tilt
-0.60
δ-decay vs time
Charm tilt -0.60: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 77 ATM contracts, 17k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 69.8% / Wing —
30 DTE / 10d
100%
+28.9
pts
EXTREME
as of Oct 26 · ATM 64.3% / Wing 93.2%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)7.2LowOct 26
IV Rank (30 DTE)6.9LowOct 26
Straddle Price (30 DTE)$13.10Oct 26
Beta Analysis
Risk Metrics
Beta: 1.0687
Alpha: 20.52%
Correlation: 0.1573
R-Squared: 2.5%
Stock Volatility: 86.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own ABVX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $191.7M | #202 of 6285 | +164.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $31.1M | #868 of 3716 | -61.4% | 13F | |
| Point72 Hedge fund Steve Cohen | $670K | #1578 of 1945 | -99.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2K | #4463 of 4729 | -76.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ABVX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 69,527,315 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
37 filers$976.12M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $327.66M | 33.57% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $213.86M | 21.91% | 2026-06-30 |
| 3 | LMR Partners LLP | $75.53M | 7.74% | 2026-06-30 |
| 4 | GREAT POINT PARTNERS LLC | $53.30M | 5.46% | 2026-06-30 |
| 5 | ExodusPoint Capital Management, LP | $49.44M | 5.06% | 2026-06-30 |
| 6 | DIADEMA PARTNERS LP | $46.53M | 4.77% | 2026-06-30 |
| 7 | Ikarian Capital, LLC | $45.45M | 4.66% | 2026-06-30 |
| 8 | ORBIMED ADVISORS LLC | $26.65M | 2.73% | 2026-06-30 |
| 9 | TUDOR INVESTMENT CORP ET AL | $21.04M | 2.16% | 2026-06-30 |
| 10 | Ally Bridge Group (NY) LLC | $16.66M | 1.71% | 2026-06-30 |
| 11 | BOOTHBAY FUND MANAGEMENT, LLC | $14.45M | 1.48% | 2026-06-30 |
| 12 | K2 PRINCIPAL FUND, L.P. | $11.34M | 1.16% | 2026-06-30 |
| 13 | Millennium Management LLC Custodian | $9.85M | 1.01% | 2026-06-30 |
| 14 | DG Capital Management, LLC | $8.89M | 0.91% | 2026-06-30 |
| 15 | Verition Fund Management LLC | $6.93M | 0.71% | 2026-06-30 |
| 16 | ADAR1 Capital Management, LLC | $5.92M | 0.61% | 2026-06-30 |
| 17 | D. E. Shaw & Co., Inc. Custodian | $5.33M | 0.55% | 2026-06-30 |
| 18 | Jane Street Group, LLC Custodian | $4.61M | 0.47% | 2026-06-30 |
| 19 | Barclays PLC Custodian | $4.22M | 0.43% | 2026-06-30 |
| 20 | Quinn Opportunity Partners LLC | $4.00M | 0.41% | 2026-06-30 |
| 21 | Kite Lake Capital Management (UK) LLP | $3.96M | 0.41% | 2026-06-30 |
| 22 | TORONTO DOMINION BANK | $3.88M | 0.40% | 2026-06-30 |
| 23 | Marex Group Ltd | $3.33M | 0.34% | 2026-06-30 |
| 24 | Persistent Asset Partners Ltd | $2.07M | 0.21% | 2026-06-30 |
| 25 | UBS Group AG Custodian | $1.96M | 0.20% | 2026-06-30 |
25 filers$541.75M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $159.99M | 29.53% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $151.28M | 27.92% | 2026-06-30 |
| 3 | DIADEMA PARTNERS LP | $33.63M | 6.21% | 2026-06-30 |
| 4 | Ikarian Capital, LLC | $33.31M | 6.15% | 2026-06-30 |
| 5 | ExodusPoint Capital Management, LP | $30.28M | 5.59% | 2026-06-30 |
| 6 | TUDOR INVESTMENT CORP ET AL | $23.95M | 4.42% | 2026-06-30 |
| 7 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | $21.32M | 3.94% | 2026-06-30 |
| 8 | LMR Partners LLP | $17.26M | 3.19% | 2026-06-30 |
| 9 | TORONTO DOMINION BANK | $16.66M | 3.07% | 2026-06-30 |
| 10 | Jane Street Group, LLC Custodian | $11.99M | 2.21% | 2026-06-30 |
| 11 | Point72 Asset Management, L.P. | $10.66M | 1.97% | 2026-06-30 |
| 12 | BOOTHBAY FUND MANAGEMENT, LLC | $10.22M | 1.89% | 2026-06-30 |
| 13 | Verition Fund Management LLC | $8.53M | 1.57% | 2026-06-30 |
| 14 | SPHERA FUNDS MANAGEMENT LTD. | $2.67M | 0.49% | 2026-06-30 |
| 15 | Walleye Trading LLC | $2.47M | 0.46% | 2026-06-30 |
| 16 | Ameriprise Financial, Inc. Custodian | $2.44M | 0.45% | 2026-06-30 |
| 17 | Balyasny Asset Management L.P. | $1.33M | 0.25% | 2026-06-30 |
| 18 | J. Goldman & Co LP | $1.27M | 0.23% | 2026-06-30 |
| 19 | Walleye Capital LLC | $866.19K | 0.16% | 2026-06-30 |
| 20 | Barclays PLC Custodian | $826.21K | 0.15% | 2026-06-30 |
| 21 | HARVEST MANAGEMENT LLC | $333.15K | 0.06% | 2026-06-30 |
| 22 | Squarepoint Ops LLC | $293.17K | 0.05% | 2026-06-30 |
| 23 | UBS Group AG Custodian | $133.26K | 0.02% | 2026-06-30 |
| 24 | RFG Advisory, LLC | $39.98K | <0.01% | 2026-06-30 |
| 25 | Persistent Asset Partners Ltd | $11.34K | <0.01% | 2026-06-30 |
ETF Holders
44 ETFs hold ABVX
25 shown · $403.74M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.02% | $111.6M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.02% | $73.7M | — | 2026-09-30 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.45% | $48.7M | $10.7B | 2026-10-23 |
| 4 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.02% | $43.5M | $189.0B | 2026-10-23 |
| 5 | EFA iShares MSCI EAFE ETF | iShares (BlackRock) | 0.03% | $20.6M | $76.4B | 2026-10-23 |
| 6 | VGK Vanguard FTSE Europe ETF | Vanguard | 0.05% | $17.7M | — | 2026-09-30 |
| 7 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.02% | $17.5M | — | 2026-09-30 |
| 8 | GVIP Goldman Sachs Hedge Industry VIP ETF | Goldman | 1.69% | $9.1M | $538.6M | 2026-10-23 |
| 9 | EFG iShares MSCI EAFE Growth ETF | iShares (BlackRock) | 0.06% | $8.2M | $14.9B | 2026-10-23 |
| 10 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.01% | $8.0M | $57.1B | 2026-10-23 |
| 11 | EZU iShares MSCI Eurozone ETF | iShares (BlackRock) | 0.08% | $7.3M | $9.1B | 2026-10-23 |
| 12 | VT Vanguard Total World Stock ETF | Vanguard | 0.01% | $6.5M | — | 2026-09-30 |
| 13 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.02% | $6.5M | $33.7B | 2026-10-23 |
| 14 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.01% | $5.5M | $40.7B | 2026-10-23 |
| 15 | IEUR iShares Core MSCI Europe ETF | iShares (BlackRock) | 0.04% | $3.5M | $9.4B | 2026-10-23 |
| 16 | ACWX iShares MSCI ACWI ex U.S. ETF | iShares (BlackRock) | 0.02% | $2.9M | $17.6B | 2026-10-23 |
| 17 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.30% | $2.3M | — | 2026-05-31 |
| 18 | ACWI iShares MSCI ACWI ETF | iShares (BlackRock) | 0.01% | $1.8M | $32.6B | 2026-10-23 |
| 19 | ATFV Alger 35 ETF | Nport | 0.86% | $1.7M | — | 2026-06-30 |
| 20 | IMTM iShares MSCI Intl Momentum Factor ETF | iShares (BlackRock) | 0.04% | $1.5M | $4.1B | 2026-10-23 |
| 21 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $1.3M | $10.7B | 2026-10-23 |
| 22 | AADR AdvisorShares Dorsey Wright ADR ETF | Nport | 3.12% | $1.3M | — | 2026-06-30 |
| 23 | ISCF iShares International Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.15% | $1.1M | $699.5M | 2026-10-23 |
| 24 | EWQ iShares MSCI France ETF | iShares (BlackRock) | 0.29% | $996,383 | $340.6M | 2026-10-23 |
| 25 | MEDI Harbor Health Care ETF | Nport | 2.16% | $891,804 | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (3 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q4 '24 | 2024-12-31 | — | — | — | — |
| Q4 '23 | 2023-12-31 | — | — | — | — |
Q4 2025 • period ending 2025-12-31 • filed 2026-03-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.78M
SI % of Float
8.88%
Days to Cover
5.05
Short Vol Ratio
37.2%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-26